DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1195582
Title:
AXL-Targeting Antibody-Drug Conjugate as Novel Therapy for Triple-Negative Breast Cancer
Report Date:
2022-10-01
Abstract:
Our recent studies discovered that AXL, a receptor protein tyrosine kinase (RTK), is selectively overexpressed and activated in highly aggressive TNBC cells. Based on this discovery in this study, we propose to establish AXL as a novel therapeutic target in the treatment of patients with TNBC. To achieve this, we will develop a novel therapeutic agent, a humanized anti-AXL ADC to specifically and effectively target TNBC with AXL over expression. Specific Aims: Aim 1. To develop a humanized antibody-drug conjugate (ADC) that can effectively target the AXL membrane receptor tyrosine kinase. Aim 2. To test the efficacy of the AXL-targeted ADC in preclinical animal models Aim 3. To develop a mass spectrometry-based method to effectively monitor AXL expression and activation in xenograft tissues and clinical samples.
Document Type:
Conference:
Journal:
Pages:
10
File Size:
0.74MB
W81XWH-19-1-0680, BC181309
(W81XWH1910680, BC181309);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
